These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 7921683)
1. [Towards a new vaccine economy?]. Poirot P; Martin JF Sante; 1994; 4(3):183-7. PubMed ID: 7921683 [TBL] [Abstract][Full Text] [Related]
2. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
4. Financial requirements of immunisation programmes in developing countries: a 2004-2014 perspective. Peny JM; Gleizes O; Covilard JP Vaccine; 2005 Aug; 23(37):4610-8. PubMed ID: 15979769 [TBL] [Abstract][Full Text] [Related]
5. The Developing Countries Vaccine Manufacturers' Network (DCVMN) is a critical constituency to ensure access to vaccines in developing countries. Jadhav S; Datla M; Kreeftenberg H; Hendriks J Vaccine; 2008 Mar; 26(13):1611-5. PubMed ID: 18294742 [TBL] [Abstract][Full Text] [Related]
6. [An analysis of the pharmaceuticals market in Vietnam]. Simonet D Sante; 2001; 11(3):155-60. PubMed ID: 11641078 [TBL] [Abstract][Full Text] [Related]
7. Vaccine supply: a cross-national perspective. Danzon PM; Pereira NS; Tejwani SS Health Aff (Millwood); 2005; 24(3):706-17. PubMed ID: 15886165 [TBL] [Abstract][Full Text] [Related]
8. A fresh injection of interest for vaccines. AIDS Anal Afr; 1998 Feb; 8(1):3, 6. PubMed ID: 12293289 [TBL] [Abstract][Full Text] [Related]
9. The impact of globalization on vaccine development and availability. Milstien JB; Kaddar M; Kieny MP Health Aff (Millwood); 2006; 25(4):1061-9. PubMed ID: 16835187 [TBL] [Abstract][Full Text] [Related]
11. Vaccine stability in the context of vaccine delivery in a developing country: India. John TJ Dev Biol Stand; 1996; 87():19-25. PubMed ID: 8853998 [TBL] [Abstract][Full Text] [Related]
13. Acellular pertussis vaccines: new preparation. Better tolerated but less active? Prescrire Int; 2000 Feb; 9(45):204-7. PubMed ID: 11503797 [TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and safety of a combined hepatitis A and B vaccine administered concomitantly with either a measles-mumps-rubella or a diphtheria-tetanus-acellular pertussis-inactivated poliomyelitis vaccine mixed with a Haemophilus influenzae type b conjugate vaccine in infants aged 12-18 months. Usonis V; Meriste S; Bakasenas V; Lutsar I; Collard F; Stoffel M; Tornieporth N Vaccine; 2005 Apr; 23(20):2602-6. PubMed ID: 15780442 [TBL] [Abstract][Full Text] [Related]
15. Progress toward introduction of Haemophilus influenzae type b vaccine in low-income countries--worldwide, 2004-2007. Centers for Disease Control and Prevention (CDC) MMWR Morb Mortal Wkly Rep; 2008 Feb; 57(6):148-51. PubMed ID: 18272957 [TBL] [Abstract][Full Text] [Related]
16. [Frontier of mycobacterium research--host vs. mycobacterium]. Okada M; Shirakawa T Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793 [TBL] [Abstract][Full Text] [Related]
19. Trends and determinants of immunisation coverage in India. Suresh K; Saxena D J Indian Med Assoc; 2000 Jan; 98(1):10-4. PubMed ID: 11016138 [TBL] [Abstract][Full Text] [Related]